SEC Form 4 · accession 0001209191-15-060391
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jul 8, 2015
Accepted (ET)
Jul 10, 2015 · 1:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2015 | M | 1,300 | $17.16 | A | 346,584 | D | |
| Common Stock | Jul 8, 2015 | M | 10,400 | $35.64 | A | 356,984 | D | |
| Common StockF2,F3 | Jul 8, 2015 | S | 2,836 | $121.64 | D | 354,148 | D | |
| Common StockF3,F4 | Jul 8, 2015 | S | 3,900 | $122.39 | D | 350,248 | D | |
| Common StockF3,F5 | Jul 8, 2015 | S | 4,264 | $123.47 | D | 345,984 | D | |
| Common StockF3,F6 | Jul 8, 2015 | S | 400 | $124.21 | D | 345,584 | D | |
| Common StockF3,F7 | Jul 8, 2015 | S | 300 | $125.38 | D | 345,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $17.16 | Jul 8, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 1,800 | D |
| Stock Option (right to buy)F8 | $35.64 | Jul 8, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 302,400 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $121.64 (range $121.00 to $121.97).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $122.39 (range $122.00 to $122.98).
- F5Open market sales reported on this line occurred at a weighted average price of $123.47 (range $123.01 to $124.00).
- F6Open market sales reported on this line occurred at a weighted average price of $124.21 (range $124.05 to $124.43).
- F7Open market sales reported on this line occurred at a weighted average price of $125.38 (range $125.15 to $125.50).
- F8Fully vested.